Term ends Feb 26, 2029 · Medium confidence
20-year base term ends Feb 26, 2029
Why Medium: A parent in the chain could not be resolved.
Held by Vanrx Pharmasystems Inc.
Filed Feb 27, 2022 as application 17/681,810 · Granted Apr 18, 2023
Base term, 20 years from filing
Today
2009
2029
Clock starts
Feb 26, 2009
Feb 26, 2009
Term ends
Feb 26, 2029
Feb 26, 2029
Granted
Apr 18, 2023
Apr 18, 2023
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,261,940, to Feb 26, 2029. The term already ends on or before that date, so the cap shortened nothing.
1 of 1
Maintenance fees paid
One maintenance fee can end this term early, the one due 3.5 years from grant; the next one's grace period runs past the term end. This counts it if the record shows it paid.
9
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 1 maintenance fees is paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Feb 26, 2009, when application 12/393,183, the earliest non-provisional in its chain, was filed (this one was filed Feb 27, 2022); a parent in its chain could not be resolved (the next row) | Feb 26, 2029 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,261,940) | resolves to Feb 26, 2029, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 1 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Feb 26, 2029 | Medium confidence |
This family
| Application 12/393,183 | Abandoned not computed | not computed |
| US 8,397,982 | Lapsed on the fee record Mar 2021 | Mar 2021 |
| US 9,789,986 | In force May 2031 | May 2031 |
| US 8,651,368 | Lapsed on the fee record Feb 2022 | Feb 2022 |
| US 10,261,940 | In force Feb 2029 | Feb 2029 |
| US 10,901,941 | In force Apr 2029 | Apr 2029 |
| Application 17/005,606 | Abandoned not computed | not computed |
| US 11,630,801 | this patent Feb 2029 | Feb 2029 |
8 of 9 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Feb 28, 2022 Reel 59121, frame 445 | Procyshyn, Christopher A; Gold, Ross M; Vanrx Pharmaceuticals Inc. | Vanrx Pharmasystems Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Feb 2029
Term ends Feb 26, 2029. No further fees fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,261,940, ends no earlier than this term, so it caps nothing.
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2023 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.